PubRank

G David Roodman

Author PubWeight™ 87.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007 2.76
2 In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010 2.03
3 A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010 1.89
4 Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011 1.81
5 Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007 1.79
6 Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006 1.77
7 Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 2008 1.74
8 Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002 1.66
9 Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2006 1.52
10 IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005 1.35
11 A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008 1.33
12 Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 2010 1.32
13 IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2003 1.29
14 Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 2005 1.24
15 Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 2012 1.24
16 MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005 1.23
17 Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2005 1.22
18 Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013 1.21
19 Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One 2009 1.20
20 Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011 1.20
21 International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013 1.19
22 Activating transcription factor 4 regulates osteoclast differentiation in mice. J Clin Invest 2010 1.19
23 Chemokines in multiple myeloma. Exp Hematol 2006 1.18
24 Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009 1.16
25 Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010 1.14
26 Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006 1.14
27 C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 2009 1.14
28 Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012 1.12
29 The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005 1.10
30 Osteoclasts are important for bone angiogenesis. Blood 2009 1.08
31 Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol 2011 1.08
32 Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 2006 1.06
33 Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. J Bone Miner Res 2004 1.05
34 Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002 1.05
35 Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 2007 1.04
36 The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw 2009 1.03
37 Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011 1.02
38 AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 2003 1.02
39 Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008 1.00
40 Cloning and characterization of the annexin II receptor on human marrow stromal cells. J Biol Chem 2006 0.99
41 (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology 2004 0.98
42 Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006 0.98
43 Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2009 0.97
44 Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 2012 0.97
45 Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res 2005 0.96
46 SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2006 0.96
47 Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem 2013 0.95
48 Management of bone disease in multiple myeloma. Expert Rev Hematol 2014 0.93
49 Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol 2010 0.92
50 Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007 0.91
51 Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011 0.91
52 Eosinophil chemotactic factor-L (ECF-L): a novel osteoclast stimulating factor. J Bone Miner Res 2003 0.90
53 Bone-breaking cancer treatment. Nat Med 2007 0.89
54 ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo. J Bone Miner Res 2011 0.89
55 Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2003 0.89
56 Mechanisms of multiple myeloma bone disease. Bonekey Rep 2012 0.88
57 Optimal use of bisphosphonates in patients with multiple myeloma. Blood 2013 0.87
58 High bone turnover markers predict poor outcome in patients with bone metastasis. J Clin Oncol 2005 0.87
59 Perspective on the osteoclast: an angiogenic cell? Ann N Y Acad Sci 2007 0.86
60 SV40 T antigen and telomerase are required to obtain immortalized human adult bone cells without loss of the differentiated phenotype. Cell Growth Differ 2002 0.85
61 Role of the microenvironment in multiple myeloma bone disease. Future Oncol 2006 0.85
62 Experimental models of Paget's disease. J Bone Miner Res 2006 0.84
63 TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res 2014 0.83
64 Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res 2014 0.83
65 Ultrastructure of bone cells in Paget's disease of bone. J Bone Miner Res 2006 0.82
66 Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem 2010 0.81
67 Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells. J Steroid Biochem Mol Biol 2004 0.80
68 Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res 2006 0.80
69 Paget's disease-a VDR coactivator disease? J Steroid Biochem Mol Biol 2004 0.79
70 Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther 2006 0.79
71 Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. J Bone Miner Res 2013 0.79
72 Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care 2014 0.78
73 Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Exp Hematol 2006 0.78
74 Bone effects of cancer therapies: pros and cons. Curr Opin Support Palliat Care 2011 0.78
75 Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest 2016 0.78
76 Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest 2016 0.78
77 Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1. Bone 2006 0.77
78 Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone 2012 0.77
79 The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 2009 0.77
80 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells. J Steroid Biochem Mol Biol 2008 0.76
81 Advances in supportive care for multiple myeloma. J Natl Compr Canc Netw 2014 0.76
82 Vitamin E: good for the heart, bad for the bones? Nat Med 2012 0.76
83 Characterization of Immortalized Osteoclast Precursors Developed from Mice Transgenic for Both bcl-XL and Simian Virus 40 Large T Antigen. Endocrinology 1999 0.75
84 SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. Arch Pharm (Weinheim) 2007 0.75
85 Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing ICAM-1 expression. Ann N Y Acad Sci 2006 0.75
86 New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol 2009 0.75